Jiutian Chemical Group Limited (C8R) AI Stock Analysis

• Market Cap: S$45.73M
• Dividend Yield: N/A
• Average Volume (3M): 5.70M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: -2.43%
• EPS Growth: 52.80%
• Country: SG
• Employees: N/A
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): >-0.01
• Shares Outstanding: 1,988,444,000
• 10 Day Avg. Volume: 2,600,530
• 30 Day Avg. Volume: 5,701,756
• PEG Ratio: -0.14
• Price to Book (P/B): 0.60
• Price to Sales (P/S): 2.54
• P/FCF Ratio: -1.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: S$0.02 ▲(10.00% Upside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is weighed down primarily by sharply deteriorating fundamentals (revenue decline, heavy losses, negative gross profit, and negative operating/free cash flow). Technicals add pressure with a negative MACD and the price trading below longer-term moving averages. Valuation offers limited support because earnings are negative and no dividend yield is provided.

Positive Factors

Moderate, improving leverage

Debt-to-equity near 0.28 materially lowers solvency risk versus highly leveraged peers. This improved capital structure gives the company durable financial flexibility to fund operations or restructuring over the next several months without immediate refinancing pressure.

Prior proven profitability (2020–2022)

A track record of robust margins and growth in 2021–2022 indicates the business model and operations can generate healthy profits. That operational capability supports the view that margins and earnings could recover if market conditions or cost structures normalize.

Exposure to Chemicals industry

Operating in the chemicals sector provides exposure to multiple industrial end-markets and enduring product demand. This structural industry placement offers long-term revenue diversification and recovery optionality as end-market cycles improve.

Negative Factors

Material revenue decline (2023–2025)

Sustained, material revenue declines erode scale and weaken the firm's ability to cover fixed costs and invest in recovery. Without a clear revenue stabilization, top-line weakness will remain a durable headwind to margin and cash-flow improvement.

Negative gross profit and large net loss

Three consecutive years of negative gross profit signal structural margin failure at the core product level. Large net losses deplete equity and constrain reinvestment, making operational recovery and competitiveness materially more difficult over the medium term.

Persistent negative operating and free cash flow

Ongoing negative operating and free cash flow create durable liquidity pressure and raise dependence on external funding. Continued cash consumption increases risk of dilution, higher borrowing costs, or constrained investment in operations and recovery initiatives.

Jiutian Chemical Group Limited Business Overview & Revenue Model

Company Description

Jiutian Chemical Group Limited, an investment holding company, manufactures and sells chemical-based products in the People's Republic of China. The company offers dimethylformamide, which is used as a feedstock in the production of polyurethane, pharmaceutical, and agro chemical products, as well as an absorbing agent primarily in electronics, acrylic fibers, and pharmaceutical products; and methylamine, a chemical feedstock in the organic chemical industry used in various areas, such as agricultural chemicals, medicines, fuels, synthetic resins, and leather making, as well as in the production of the solvent used for chemical fibers, activating agents, and photography. It also provides sodium hydrosulfite, a crystalline powder for use in water treatment, gas purification, cleaning, and stripping, as well as in the industrial processing of textiles, leather, foods, polymers, photography, and others; industrial and consumable carbon dioxide for use in aerated beverages, tobacco, and preserving vegetables; Oxygen-18, an isotope of oxygen to produce fluorodeoxyglucose; deuterium depleted water to inhibit cancer growth; and industrial methanol. In addition, the company is involved in the sale of downstream products; and research and development of isotope technology. Jiutian Chemical Group Limited was founded in 1994 and is based in Singapore.

How the Company Makes Money

Jiutian Chemical Group Limited generates revenue through multiple streams, primarily by manufacturing and selling its chemical products to various industries. The company's revenue model is based on the volume of chemicals produced and sold, as well as the pricing strategies employed for different product lines. Key revenue streams include direct sales to manufacturers in sectors like agriculture, automotive, and construction. Additionally, Jiutian may engage in long-term contracts with major clients, providing a steady income flow. The company also benefits from strategic partnerships with distributors and suppliers, enhancing its market reach and operational efficiency. Factors contributing to its earnings include fluctuations in raw material prices, demand for specialty chemicals, and the overall health of the global chemical market.

Jiutian Chemical Group Limited Financial Statement Overview

Summary

Financial results have deteriorated significantly since 2022: revenue declined materially in 2023–2025, profitability flipped to deeply negative (including negative gross profit in the last three annual reports), and 2025 ended with a large net loss. Cash generation is also weak with operating cash flow and free cash flow negative in 2023–2025. Balance-sheet leverage is a partial offset (debt-to-equity improved to ~0.28 in 2025), but ongoing losses and negative ROE elevate financial risk.

Income Statement

Performance has deteriorated sharply after 2022. Revenue fell materially in 2023–2025, and profitability flipped from healthy positive margins in 2020–2022 to deeply negative margins in 2023–2025 (including negative gross profit in the last three annual reports), culminating in a large net loss in 2025. The only clear strength in the history provided is the strong profitability and growth profile seen in 2021–2022, but the recent trajectory is decisively unfavorable.

Balance Sheet

Leverage looks moderate with debt below equity across the period (debt-to-equity improving to ~0.28 in 2025 from higher levels earlier), which is a stabilizing factor. However, recurring large losses have driven negative returns on equity in 2023–2025, raising risk that continued losses could erode the equity base over time despite the currently reasonable leverage.

Cash Flow

Cash generation weakened meaningfully: operating cash flow and free cash flow turned negative in 2023–2025 after being strongly positive in 2020–2022. While free cash flow improved versus 2023 and 2024 (less negative in 2025), the business is still consuming cash and operating cash flow remains negative, which increases funding and liquidity pressure if the trend persists.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	393.13M	106.22M	243.76M	598.56M	2.43B	2.17B
Gross Profit	-147.20M	-106.22M	-82.26M	-260.18M	708.41M	675.62M
EBITDA	-141.98M	-96.04M	-118.22M	-321.76M	696.61M	517.79M
Net Income	-162.31M	-165.01M	-147.80M	-344.64M	490.50M	324.90M
Balance Sheet
Total Assets	1.42B	699.69M	1.05B	1.29B	1.99B	1.89B
Cash, Cash Equivalents and Short-Term Investments	698.48M	198.16M	400.41M	529.62M	1.11B	773.55M
Total Debt	234.88M	127.62M	289.32M	265.88M	134.64M	228.18M
Total Liabilities	469.16M	248.45M	427.02M	523.23M	764.65M	1.08B
Stockholders Equity	948.17M	451.24M	618.04M	765.84M	1.22B	816.21M
Cash Flow
Free Cash Flow	-356.18M	-155.06M	-171.63M	-511.23M	424.05M	633.54M
Operating Cash Flow	-328.39M	-129.87M	-81.58M	-385.65M	434.01M	655.81M
Investing Cash Flow	-27.72M	-24.57M	-89.54M	-125.70M	-9.85M	-27.68M
Financing Cash Flow	-53.04M	-160.50M	32.87M	-732.00K	-95.52M	-110.89M

Jiutian Chemical Group Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:C8R, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.20 is Neutral, neither overbought nor oversold. The STOCH value of -63.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:C8R.

Jiutian Chemical Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
C05	52 Neutral	S$37.97M	-1.64	-19.55%	0.92%	-7.45%	-480.22%
C8R	43 Neutral	S$45.73M	-1.51	-20.85%	―	-2.43%	52.80%

Jiutian Chemical Group Limited Corporate Events

Jiutian Chemical Drops Synthetic Ammonia Investment Amid Tightening China Credit

Jiutian Chemical Group has mutually agreed with Anyang Chemical Industry Group to terminate its planned investment in a synthetic ammonia project and the lease of a urea production facility in China, after reassessing the project’s commercial viability amid tighter lending conditions and stricter collateral and repayment requirements across the Chinese banking sector. The company stated that key conditions precedent, particularly securing adequate bank financing, could not be met, but emphasized that it has incurred no material capital expenditure, faces no penalties or break fees from the termination, and does not expect any material adverse impact on its financial position for the 2025 financial year; it will continue to evaluate other strategic and investment opportunities aligned with its long-term objectives and shareholder interests.

The most recent analyst rating on (SG:C8R) stock is a Hold with a S$0.03 price target. To see the full list of analyst forecasts on Jiutian Chemical Group Limited stock, see the SG:C8R Stock Forecast page.